A Leiden University Medical Center spin-off developing first-in-class small-molecule therapies to restore vascular stability in diseases associated with pericyte dysfunction
A Leiden University Medical Center spin-off developing first-in-class small-molecule therapies to restore vascular stability in diseases associated with pericyte dysfunction. Its lead program, RTX-001, is a potential once-daily oral treatment for hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder.